Socratic dialogue: the future management of hyperlipidaemia

Br J Cardiol 2003;10(Suppl 2):S1-S6 Leave a comment
Click any image to enlarge
Sponsorship Statement: This is a sponsored supplement to The British Journal of Cardiology. Details of sponsorship can be found by downloading the PDF.

The Greek philosopher Socrates developed the technique of challenging accepted wisdom through rigorous questioning, with the aim of establishing a better understanding of a subject through a logical assessment of the facts, rather than the pressures of convention. In the Socratic dialogue on the future management of hyperlipidaemia, Professor John Betteridge was joined by six multidisciplinary experts to discuss the strengths and weaknesses of current treatment pathways in cholesterol management, the opportunities, and the barriers to best practice.

Professor Betteridge challenged the group with the  statement that current cholesterol management often  fails the patient: treatments do ‘marvellously well’ in  clinical trials yet clinicians fail their patients by not effectively  explaining the benefits of cholesterol management  to them. In addition, he asked the group to consider  why patients receiving treatment are often not  achieving the cholesterol-lowering goals currently set  by the National Service Framework for Coronary Heart  Disease (NSF for CHD). These are: total cholesterol (TC)  < 5 mmol/L and low-density lipoprotein (LDL) cholesterol  < 3 mmol/L or reduced by 30% (whichever is  greater).1 Professor Betteridge emphasised the importance  of addressing the clinical and organisational reasons  for this, in order to ensure that patients are properly  and adequately treated on the basis of the best  available scientific data.

Disclaimer: UK prescribing information current at the date of publication of this supplement can be found by downloading the PDF. Medinews Cardiology Limited advises healthcare professionals to consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews Cardiology Limited cannot accept responsibility for any errors in prescribing which may occur.